Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS) between August 8, 2011 and September 20, 2013, inclusive (the “Class Period”), have until November 29, 2013, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of New York.
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
BioScrip provides home care services and pharmacy benefit management services in the United States. On September 23, 2013, the Company disclosed that the United States Attorney’s Office for the Southern District of New York and the New York State Attorney General’s Medicaid Fraud Control Unit have undertaken an investigation regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade (R) by the Company’s specialty pharmacy division. The Company further disclosed that it has provided documents and information to the government regarding the distribution of Exjade, pursuant to a civil investigative demand and a subpoena. The Complaint alleges that defendants failed to disclose that the Company improperly distributed Exjade through its specialty pharmacy operations, and was in violation of certain federal and state laws and regulations.
To learn more about this action, or if you have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.